Action on Hearing Loss Logo
    Total results:
    Search
      Total results:

      Drug to reduce hearing loss due to cancer treatments is now available

      Some cancer survivors develop hearing loss, caused by the drugs that treat cancer. A US-based company, Fennec Pharmaceuticals, have developed a new drug that prevents hearing loss in children who have been treated for liver cancer. Dr Carina Santos, from our research team, tells us more.

      By: Carina Santos | 20 November 2017

      Cancer is a devastating disease but for some people, surviving cancer does not always mean going back to a normal life. Some cancer survivors have to face a life with severe hearing loss caused by their life-saving chemotherapy. The consequences of hearing loss can be particularly devastating in children, impacting on their language and social development.

      Cisplatin is a platinum-based compound widely used in chemotherapy treatments, especially in children‘s cancers because it is highly effective - 80% survival rates. However, this drug can lead to permanent and severe high frequency hearing loss in 6 out of every 10 children following treatment. Hearing loss can occur within hours or days after the first cycle of cisplatin treatment, or develop after repeated rounds of treatment. Many of these children will require hearing aids or cochlear implants for the rest of their lives. However, the adaptation of a child to hearing aids is not easy and a lot of them end up not using them properly. (For real testimonies of mothers dealing with the hearing loss of their children after cancer treatment please watch here and here)

      Fennec Pharmaceuticals is a US-based pharmaceutical company that is developing a drug (Sodium Thiosulfate (STS)) to reduce cisplatin-induced hearing loss in children.  They recently presented their results from Phase III clinical trials – the final stage of clinical testing before a drug is approved for use. The results show that 67% of children with standard risk hepatoblastoma (a type of liver cancer) treated with cisplatin developed hearing loss, compared to just 37% of children that were treated with cisplatin + STS. Fennec pharmaceuticals has also shown that if STS is given 6 hours after cisplatin treatment it could still help protect hearing without interfering with cisplatin’s ability to kill cancer (you can watch Dr. Penelope Brock, MD, of Great Ormond Street Hospital in London, UK, explaining the results here).

      Fennec Pharmaceuticals will now apply for a license from the Food and Drug Administration in the USA and the European Medicines Agency so that they can market and sell the drug they have developed. In the meantime, before it is licensed, parents of children with hepatoblastoma undergoing chemotherapy who wish to protect their children’s hearing with STS can access it under a special scheme called the Named Patient Programme, also known as Compassionate Use Program. These are programmes created by regulators to allow patients with an unmet medical need to have access to promising drugs that are in late-stages of development before they have been approved. You can find out more information about this drug and its Named Patient Programme in the links below.

      To see more about STS please consult Fennec Pharmaceuticals webpage: http://fennecpharma.com/

      Press release of clinical trials results: http://fennecpharma.com/fennec-announces-positive-results-from-phase-3-siopel-6-study-on-pedmark-sodium-thiosulfate-presented-at-the-49th-congress-of-the-international-society-of-pediatric-oncology-siop-2017-mee/

      STS Named Patient Programme: http://fennecpharma.com/fennec-announces-launch-of-european-named-patient-programme-for-sodium-thiosulfate-for-pediatric-patients-with-standard-risk-hepatoblastoma/

      Recent Posts

      Could ‘chemical earmuffs’ prevent noise-induced hearing damage?

      Researchers in the US have identified molecules in the inner ear that are involved in the damage that loud noise causes to hearing. Blocking their activity protected against this damage when mice were exposed to loud noise. These findings could form the basis of new treatments to protect people’s hearing from noise.

      By: Tracey Pollard
      16 March 2020

      Helping patients to be heard: What the new NICE guidance means for people with tinnitus

      Imagine you’re trying to enjoy a moment of silence, but it’s interrupted by a relentless ringing noise. What if this happened all day, every day? That’s persistent tinnitus, and as an audiologist, I see the impact of this condition every day.

      By: Vai Maheswaran
      11 March 2020

      A clinical trial of a new investigational drug for vertigo in Ménière’s disease - OTO-104

      A clinical study team are looking for volunteers to test their new investigational drug, OTO-104, for vertigo episodes in Ménière’s disease.

      By: The OTO-104 Study Team
      11 March 2020

      Our future research leaders

      Last month, we invited our PhD students and our early-career Fellows to visit our head office in Highbury, to find out more about the work we do, to meet each other and to meet our staff. Marta Narkiewicz, from our research team, tells us more about the day.

      By: Marta Narkiewicz
      10 March 2020